Methyl 6-(2,2-dimethyl-1-oxopropyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate | 1259287-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: Methyl 6-(2,2-dimethyl-1-oxopropyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate
• 英文别名: methyl 6-(2,2-dimethylpropanoyl)-5,7-dihydro-4H-thieno[2,3-c]pyridine-2-carboxylate
• CAS: 1259287-87-0
• 化学式: C₁₄H₁₉NO₃S
• 分子量: 281.376
• InChiKey: OBIREQDQIDCVBU-UHFFFAOYSA-N

物化性质

• 沸点：
  460.1±45.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 6-(2,2-dimethyl-1-oxopropyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate 在 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以12%的产率得到6-(2,2-dimethylpropanoyl)-N-hydroxy-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxamide
  参考文献：
  名称：

  [EN] SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  [FR] ACIDES HYDROXAMIQUES SUBSTITUÉS ET LEURS UTILISATIONS

  摘要：

  这项发明提供了式(/)的化合物：其中R1、R2、G、n、p和q的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、传染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。

  公开号：

  WO2010151317A1
• 作为产物：
  描述：

  methyl 6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate 在 1-氯乙基氯甲酸酯 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 23.5h， 生成 Methyl 6-(2,2-dimethyl-1-oxopropyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-carboxylate
  参考文献：
  名称：

  Potent Histone Deacetylase Inhibitors Derived from 4-(Aminomethyl)-N-hydroxybenzamide with High Selectivity for the HDAC6 Isoform

  摘要：

  A screen for HDAC6 inhibitors identified acyl derivatives of 4-(aminomethyl)-N-hydroxybenzamide as potent leads with unexpected selectivity over the other subtypes. We designed and synthesized constrained heterocyclic analogues such as tetrahydroisoquinolines that show further enhanced HDAC6 selectivity and inhibitory activity in cellular assays. Selectivity may be attributed to the benzylic spacer more effectively accessing the wider channel of HDAC6 compared to other HDAC subtypes as well as hydrophobic capping groups interacting with the protein surface near the rim of the active site.

  DOI：

  10.1021/jm400385r

文献信息

• [EN] SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF<br/>[FR] ACIDES HYDROXAMIQUES SUBSTITUÉS ET LEURS UTILISATIONS
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010151317A1

  公开（公告）日：2010-12-29

  This invention provides compounds of formula (/): wherein R1, R2, G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式(/)的化合物：其中R1、R2、G、n、p和q的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、传染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• Substituted hydroxamic acids and uses thereof
  申请人：Blackburn Christopher

  公开号：US20110046157A1

  公开（公告）日：2011-02-24

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物： 其中R1、R2、G、n、p和q的值如说明书所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明中的化合物的制药组合物以及使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或紊乱的方法。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20140329836A1

  公开（公告）日：2014-11-06

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物：其中R1、R2、G、n、p和q的值如规范所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。
• Potent Histone Deacetylase Inhibitors Derived from 4-(Aminomethyl)-<i>N</i>-hydroxybenzamide with High Selectivity for the HDAC6 Isoform
  作者：Christopher Blackburn、Cynthia Barrett、Janice Chin、Kris Garcia、Kenneth Gigstad、Alexandra Gould、Juan Gutierrez、Sean Harrison、Kara Hoar、Chrissie Lynch、R. Scott Rowland、Chris Tsu、John Ringeling、He Xu

  DOI：10.1021/jm400385r

  日期：2013.9.26

  A screen for HDAC6 inhibitors identified acyl derivatives of 4-(aminomethyl)-N-hydroxybenzamide as potent leads with unexpected selectivity over the other subtypes. We designed and synthesized constrained heterocyclic analogues such as tetrahydroisoquinolines that show further enhanced HDAC6 selectivity and inhibitory activity in cellular assays. Selectivity may be attributed to the benzylic spacer more effectively accessing the wider channel of HDAC6 compared to other HDAC subtypes as well as hydrophobic capping groups interacting with the protein surface near the rim of the active site.